Clinical Trials Logo
  1. Home
  2. Cancer of Liver
  3. NCT05643833
  4. Details
NCT05643833 Clinical Trial

Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma

Cancer of Liver Clinical Trial

Official title:
Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma: A Multicenter Retrospective Study in China

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05643833
Other study ID # CT2022-ZJU-OBS1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date October 15, 2022

Study information
Verified date November 2022
Source Zhejiang University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a large-scale study in China to provide evidence and insights in the role of gender in LT for HCC by analyzing the data of 3769 recipients with HCC registered in the China Liver Transplant Registry.

Recruitment information / eligibility
Status Completed
Enrollment 3769
Est. completion date October 15, 2022
Est. primary completion date May 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: The patients with liver transplants performed from January 2015 to December 2020, whose clinicopathological data were registered in the CLTR. Exclusion Criteria: Patients with following features were excluded: with concurrent other malignancies, pathologically-confirmed tumor types other than HCC, such as intrahepatic cholangiocarcinoma (ICC), combined hepatocellular cholangiocarcinoma (cHCC-CC), fibrolamellar hepatocellular carcinoma (FLC) or secondary metastatic tumor; without histological confirmation of HCC for transplantation. The patients who received living donor liver transplantation, split liver transplantation, reduced-size liver transplantation or simultaneous transplantation were also excluded. Next, pediatric patients (<18 years) or senile patients (>65 years) and those patients who died within six months after transplantation were also excluded. Finally, the patients with type-1 and type-2 portal vein tumor thrombus (PVTT), tumor metastasis, having doubtful or contradictory data or missing essential data for analysis, re-transplantation during follow-up time were excluded as well.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• no intervention
no intervention

Locations
Country Name City State
China Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang

Sponsors (1)
Lead Sponsor Collaborator
Zhejiang University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Overall survival the overall survival of liver transplant recipient with HCC January 2015 to December 2020
See also
  Status Clinical Trial Phase
Completed NCT01627808 - Fluid Optimization in Liver Surgery N/A
Withdrawn NCT05109052 - Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed NCT05030090 - Integrative Nutrition Care Plan for the Patient With Liver and Colorectal Cancer N/A
Terminated NCT00669136 - Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma Phase 1
Not yet recruiting NCT05041335 - Wet Heparinized Suction for Abdominal Cancer N/A
Recruiting NCT04258813 - Onco-primary Care Networking to Support TEAM-based Care N/A
Completed NCT03299036 - Drug-loadable（T-ACE Beads）for Hepatoma Embolization Therapy N/A
Recruiting NCT03323996 - Impact of a Training in Therapeutic Education on the Relation Between Care Givers and Their Patients N/A
Completed NCT02044224 - Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Phase 4
Not yet recruiting NCT03607643 - A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Phase 1/Phase 2
Recruiting NCT03452774 - SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Not yet recruiting NCT03766776 - Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC) N/A
Completed NCT02016391 - Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Phase 4
Recruiting NCT00730860 - Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE N/A
Terminated NCT00216437 - Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma Phase 1
Completed NCT04172714 - Low-dose Y90 Treatment Planning for HCC N/A
Active, not recruiting NCT03347162 - Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer
Completed NCT05907772 - Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma